Open AccessJournal Article
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Shaul G. Massry,Jack W. Coburn,Glenn M. Chertow,Keith A. Hruska,Craig B. Langman,Hartmut H. Malluche,Kevin J. Martin,Linda McCann,James T. McCarthy,Sharon M. Moe,Isidro B. Salusky,Donald J. Sherrand,Miroslaw Smogorzewski,Kline Bolton,Charles Turkelson,Karyn A. Tappe,Stephen Tregear,James Reston,Wendy Bruening,Mark Monteforte,Janice Kaczmarek,Vivian Coates,George R. Bailie,Bryan N. Becker,Gavin J. Becker,Jerrilynn D. Burrowes,Fernando Carrera,David N. Churchill,Allan J. Collins,Peter W. Crooks,Dick DeZeeuw,Thomas A. Golper,Frank A. Gotch,Antonio M. Gotto,Roger Greenwood,Joel W. Greer,Richard H. Grimm,William E. Haley,Ronald J. Hogg,Alan R. Hull,Lawrence G. Hunsicker,Cynda Ann Johnson,Michael J. Klag,Saulo Klahr,Norbert Lameire,Francesco Locatelli,Sally McCulloch,Maureen Michael,Joseph V. Nally,John M. Newmann,Allen R. Nissenson,Keith C. Norris,Gregorio T. Obrador,William F. Owen,Thakor G. Patel,Glenda Payne,Claudio Ronco,Rosa A. Rivera-Mizzoni,Anton C. Schoolwerth,Robert A. Star,Michael W. Steffes,Theodore I. Steinman,John Pierre Wauters,Nanette K. Wenger,Josephine P. Briggs,Thomas H. Hostetter,Garabed Eknoyan,Aderra Levin,Nathan W. Levin,Sharon Andreoli,Sally Burrows-Hudson,Derrick Latos,Donna Mapes,Edith Oberley,Brian J.G. Pereira,Nadine Ferguson,Donna Fingerhut,Anthony Gucciardo,Margaret Klette,Doreen Mallard,Kerry Willis +80 more
Reads0
Chats0
About:
This article is published in American Journal of Kidney Diseases.The article was published on 2003-10-01 and is currently open access. It has received 2609 citations till now. The article focuses on the topics: Chronic kidney disease-mineral and bone disorder & Kidney disease.read more
Citations
More filters
Journal ArticleDOI
Which Targets in Clinical Practice Guidelines Are Associated with Improved Survival in a Large Dialysis Organization
Francesca Tentori,William C. Hunt,Mark Rohrscheib,Min Zhu,Christine A. Stidley,Karen S. Servilla,Dana C. Miskulin,Klemens B. Meyer,Edward J. Bedrick,H. Keith Johnson,Philip G. Zager +10 more
TL;DR: It was postulated that having multiple parameters that satisfy the current guidelines, except for BP, is associated with improved survival among HD patients, and a randomized, controlled trial is needed to identify the optimal BP for HD patients.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis
Michel Chonchol,Francesco Locatelli,Hanna E. Abboud,Chaim Charytan,Angel L.M. de Francisco,Shivinder S. Jolly,Mark Kaplan,Simon D. Roger,Shyamal Sarkar,Moetaz Albizem,T. Christian H. Mix,Yumi Kubo,Geoffrey A. Block +12 more
TL;DR: It is shown that cinacalcet treatment in patients with CKD not receiving dialysis can decrease plasma iPTH levels, but with frequent (albeit generally asymptomatic) serum calcium levels less than 8.4 mg/dL and increases in serum phosphorus levels.
Journal ArticleDOI
The Influence of Glomerular Filtration Rate and Age on Fibroblast Growth Factor 23 Serum Levels in Pediatric Chronic Kidney Disease
Justine Bacchetta,Laurence Dubourg,Laurence Dubourg,Jérôme Harambat,Bruno Ranchin,Pauline Abou-Jaoude,Simone Arnaud,Marie-Christine Carlier,Michel Richard,Michel Richard,Pierre Cochat +10 more
TL;DR: Age, GFR, body mass index, and solid organ transplantation seem to influence FGF23 serum levels in a pediatric population of 227 CKD children.
Journal ArticleDOI
Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.
Mehmet Kanbay,Mahmut Ilker Yilmaz,Mugurel Apetrii,Mutlu Saglam,Halil Yaman,Hilmi Umut Unal,Mahmut Gok,Kayser Caglar,Yusuf Oguz,Mujdat Yenicesu,Hakki Cetinkaya,Tayfun Eyileten,Cengizhan Acikel,Abdulgaffar Vural,Adrian Covic +14 more
TL;DR: This observational cohort study showed that magnesium may be an independent predictor of future cardiovascular outcomes and is the first study demonstrating such a role in etiologically diagnosed CKD patients, across different stages.
Journal ArticleDOI
Successful treatment of calciphylaxis with cinacalcet—an alternative to parathyroidectomy?
TL;DR: The newly developed calcimimetic, cinacalcet (marketed as Mimpara in the EU, and as Sensipar in the USA by Amgen Inc., Thousand Oaks, CA, USA) produces rapid biochemical control of secondary hyperparathyroidism, and thus may represent an alternative treatment for patients with calciphylaxis.
References
More filters
Journal ArticleDOI
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Geoffrey A. Block,Kevin J. Martin,Angel L.M. de Francisco,Stewart A. Turner,Morrell M. Avram,Michael Suranyi,Gavril Hercz,John Cunningham,Ali K. Abu-Alfa,Piergiorgio Messa,Daniel W. Coyne,Francesco Locatelli,Raphael M. Cohen,Pieter Evenepoel,Sharon M. Moe,Albert Fournier,Johann Braun,Laura C. McCary,Valter J. Zani,Kurt Olson,Tilman B. Drüeke,William G. Goodman +21 more
TL;DR: Cinacalcet lowers parathyroid hormone levels and improves calcium-phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.